Advertisement
UK markets closed

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    83.54
    +0.73 (+0.88%)
     

  • GOLD FUTURES

    2,343.30
    +4.90 (+0.21%)
     

  • DOW

    37,988.66
    -472.26 (-1.23%)
     

  • Bitcoin GBP

    51,603.19
    +126.88 (+0.25%)
     

  • CMC Crypto 200

    1,394.31
    +11.73 (+0.85%)
     

  • NASDAQ Composite

    15,558.17
    -154.58 (-0.98%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BTG gets triple dose of good news on new products

Reuters - UK Focus

LONDON, Dec 14 (Reuters) - Specialist medicine company BTG (Other OTC: BTGYY - news) received a triple dose of good news on Monday as U.S (Other OTC: UBGXF - news) . regulators approved two new treatments and a clinical trial of a novel lung device produced positive results.

U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumours, and the success of PneumRx coils in severe emphysema may go some way to counter recent disappointment over sales of BTG (LSE: BTG.L - news) 's varicose vein treatment Varithena. (Reporting by Ben Hirschler, editing by Louise Heavens)